Press release
Given the increasing number of licensing deals and the expected approval of multiple mid-late stage candidates, the encapsulated cell therapies and encapsulation technologies market is anticipated to evolve at a rapid pace over the next decade, predicts R
To order this 500+ page report, which features 170+ figures and 395+ tables, please visit this link - https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
Key Market Insights
Presently, over 45 encapsulated cell therapies and encapsulation technologies are being evaluated across different phases of development by stakeholders across the world
Ongoing therapy development programs are evaluating different types of cells, encapsulated in a wide range of biocompatible materials, aiming to offer viable and effective treatment options for various diseases
In fact, majority of the product candidates are being developed for the treatment of metabolic disorders, primarily diabetes; big pharma are driving a significant proportion of research and development activity
Clinical research in this field is growing at a fast pace; encapsulated therapy products are evaluating a number of pre-marketing end points to validate safety / efficacy
Over the years, more than 3,000 patents have been granted / filed related to cell encapsulation technologies, demonstrating the heightened pace of research in this domain
Foreseeing a lucrative future, several private and public investors have made capital investments worth approximately USD 1 billion, across over 100 funding instances, since 2013
Growth in partnership activity reflects the rising interest of stakeholders in this domain; over 70% of deals have been inked related to therapies for metabolic disorders, involving both international and indigenous parties
An evaluation of more than 300+ stakeholders engaged in cell therapies domain reveals the presence of several likely strategic partners spread across different geographical regions
The short term opportunity in this market is likely to be driven by licensing activity and will depend on the untapped potential of novel cell encapsulation technologies in different application areas
As multiple mid-late stage encapsulated cell therapies get commercialized in near future across different regions, the long term opportunity is likely to be distributed across diverse indications and encapsulation materials
The enormous potential of encapsulated cell-based therapies / devices in the treatment of chronic disorders has captured the interest of several stakeholders in the industry
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. An Overview of Cell Therapies
3.2.1. Cell Therapy Manufacturing
3.2.2. Supply Chain
3.2.3. Key Challenges
3.3. An Introduction to Cell Encapsulation
3.3.1. Historical Overview
3.3.2. Cell Encapsulation Approaches
3.3.3. Encapsulation Materials
3.3.4. Advantages and Challenges
3.4. Potential Applications of Cell Encapsulation
3.4.1. Targeted Drug / Therapy Delivery
3.4.2. Immunoprotection
3.4.3. Storage and Transportation
3.5. Key Growth Drivers and Road-blocks
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Encapsulated Cell Therapies and Encapsulation Technologies: Developer Landscape
4.2.1. Distribution by Year of Establishment
4.2.2. Distribution by Geographical Location
4.2.3. Distribution by Size of Developers
4.2.4. Distribution by Type of Offering
4.3. Encapsulated Cell Therapies and Encapsulation Technologies: Development Pipeline
4.3.1. Distribution by Target Therapeutic Area
4.3.2. Distribution by Phase of Development
4.3.3. Distribution by Type of Cells and Other Encapsulated Components
4.3.4. Distribution by Type of Encapsulation Material Used
4.3.5. Distribution by Route of Administration
4.3.6. Distribution by Application Areas
4.4. Encapsulated Cell Therapies and Encapsulation Technologies: Initiatives of Big Pharmaceutical Players
5. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR METABOLIC DISORDERS: COMPANY PROFILES
5.1. Chapter Overview
5.2. Developers with Clinical Candidates
5.2.1. Beta-O2 Technologies
5.2.1.1. Company Overview
5.2.1.2. Financial Information
5.2.1.3. Product Description: ꞵAir Bio-artificial Pancreas
5.2.1.4. Recent Developments and Future Outlook
5.2.2. Diatranz Otsuka
5.2.2.1. Company Overview
5.2.2.2. Financial Information
5.2.2.3. Product Description: DIABECELL®
5.2.2.4. Recent Developments and Future Outlook
5.2.3. Sernova
5.2.3.1. Company Overview
5.2.3.2. Financial Information
5.2.3.3. Product Description: Cell Pouch System™
5.2.3.4. Recent Developments and Future Outlook
5.2.4. ViaCyte
5.2.4.1. Company Overview
5.2.4.2. Financial Information
5.2.4.3. Product Description: PEC-Direct™ and PEC-Encap™
5.2.4.4. Recent Developments and Future Outlook
5.3. Developers with Preclinical Candidates
5.3.1. ALTuCELL
5.3.2. Beta-Cell
5.3.3. Betalin Therapeutics
5.3.4. CellProtect Biotechnology
5.3.5. Defymed
5.3.6. Encellin
5.3.7. Kadimastem
5.3.8. PharmaCyte Biotech
5.3.9. Semma Therapeutics
5.3.10. Sigilon Therapeutics
5.3.11. Seraxis
5.3.12. SymbioCellTech
6. ENCAPSULATED CELL THERAPIES AND ENCAPSULATION TECHNOLOGIES FOR NON-METABOLIC DISORDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Developers with Clinical Candidates
6.2.1. Azellon Cell Therapeutics
6.2.1.1. Company Overview
6.2.1.2. Financial Information
6.2.1.3. Product Description: Cell Bandage
6.2.1.4. Recent Developments and Future Outlook
6.2.2. EryDel
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Product Description: EryDex System
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Erytech Pharma
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Product Description: GRASPA®
6.2.3.4. Recent Developments and Future Outloo
6.2.4. Gloriana Therapeutics
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Product Description: EC-NGF
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Living Cell Technologies
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Product Description: NTCELL®
6.2.5.4. Recent Developments and Future Outlook
6.2.6. MaxiVAX
6.2.6.1. Company Overview
6.2.6.2. Financial Information
6.2.6.3. Product Description: MVX-ONCO-1
6.2.6.4. Recent Developments and Future Outlook
6.2.7. Neurotech Pharmaceuticals
6.2.7.1. Company Overview
6.2.7.2. Financial Information
6.2.7.3. Product Description: NT-501
6.2.7.4. Recent Developments and Future Outlook
6.2.8. PharmaCyte Biotech
6.2.8.1. Company Overview
6.2.8.2. Financial Information
6.2.8.3. Product Description: Cell-in-a-Box®
6.2.8.4. Recent Developments and Future Outlook
6.3. Developers with Preclinical Candidates
6.3.1. Beta-O2 Technologies
6.3.2. Sernova
6.3.3. Sigilon Therapeutics
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Emerging Focus Areas
7.3.5. Leading Players: Analysis by Number of Patents
7.4. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Benchmarking Analysis (Industry Players)
7.4.1. Analysis by Patent Characteristics
7.4.2. Analysis by Geographical Locatio
7.5. Encapsulated Cell Therapies and Encapsulation Technologies: Patent Valuation Analysis
7.6. Leading Patents: Analysis by Number of Citations
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Clinical Trials
8.3.1. Analysis by Trial Registration Year
8.3.2. Geographical Analysis by Number of Clinical Trials
8.3.3. Geographical Analysis by Enrolled Patient Population
8.3.4. Analysis by Phase of Development
8.3.5. Analysis by Study Design
8.3.6. Analysis by Type of Sponsor / Collaborator
8.3.7. Most Active Players: Analysis by Number of Registered Trials
8.3.8. Analysis by Trial Focus
8.3.9. Analysis by Therapeutic Area
8.3.10. Analysis by Clinical Endpoints
9. RECENT PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Analysis by Type of Cells and Other Encapsulated Components
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players
9.3.6.2. Intercontinental and Intracontinental Agreements
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. Encapsulated Cell Therapies and Encapsulation Technologies: Recent Funding Instances
10.3.1. Analysis by Number of Funding Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Indications
10.3.5. Analysis by Amount Invested across Different Type of Cells and Other Encapsulated Components
10.3.6. Most Active Players: Analysis by Amount Invested
10.3.7. Most Active Investors: Analysis by Number of Instances
10.3.8. Geographical Analysis of Amount Invested
10.4. Concluding Remarks
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
11. GRANT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Encapsulated Cell Therapies and Encapsulation Technologies: List of Academic Grants
11.3.1. Analysis by Project Start Year
11.3.2. Analysis by Focus Area
11.3.3. Analysis by Support Period
11.3.4. Analysis by Type of Grant
11.3.5. Analysis by Amount Awarded
11.3.6. Analysis by Study Section
11.3.7. Analysis by Therapeutic Area
11.3.8. Analysis by Type of Cells and Other Encapsulated Components
11.3.9. Analysis by Type of Encapsulation Material
11.3.10. Leading Funding Institutes: Analysis by Number of Grants
11.3.11. Leading Recipient Organizations: Analysis by Number of Grants
12. POTENTIAL STRATEGIC PARTNERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Cell Therapy Development
12.3.1. Opportunities in North America
12.3.1.1. Most Likely Partners for Cell Therapy Development
12.3.1.2. Likely Partners for Cell Therapy Development
12.3.1.3. Less Likely Partners for Cell Therapy Development
12.3.2. Opportunities in Europe
12.3.2.1. Most Likely Partners for Cell Therapy Development
12.3.2.2. Likely Partners for Cell Therapy Development
12.3.2.3. Less Likely Partners for Cell Therapy Development
12.3.3. Opportunities in Asia-Pacific and Rest of the World
12.3.3.1. Most Likely Partners for Cell Therapy Development
12.3.3.2. Likely Partners for Cell Therapy Development
12.3.3.3. Less Likely Partners for Cell Therapy Development
12.4. Potential Strategic Partners for Cell Therapy Manufacturing
12.4.1. Opportunities in North America
12.4.1.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.1.2. Likely Partners for Cell Therapy Manufacturing
12.4.1.3. Less Likely Partners for Cell Therapy Manufacturing
12.4.2. Opportunities in Europe
12.4.2.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.2.2. Likely Partners for Cell Therapy Manufacturing
12.4.2.3. Less Likely Partners for Cell Therapy Manufacturing
12.4.3. Opportunities in Asia-Pacific and Rest of the World
12.4.3.1. Most Likely Partners for Cell Therapy Manufacturing
12.4.3.2. Likely Partners for Cell Therapy Manufacturing
12.4.3.3. Less Likely Partners for Cell Therapy Manufacturing
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Cell Encapsulation Technologies Market, 2019-2030
13.3.1. Cell Encapsulation Technologies Market by Upfront Payments, 2019-2030
13.3.2. Cell Encapsulation Technologies Market by Milestone Payments, 2019-2030
13.4. Overall Encapsulated Cell Therapies Market, till 2030
13.4.1. Encapsulated Cell Therapies Market: Distribution by Therapeutic Area
13.4.1.1. Encapsulated Cell Therapies Market for Eye Disorders, till 2030
13.4.1.2. Encapsulated Cell Therapies Market for Metabolic Disorders, till 2030
13.4.1.3. Encapsulated Cell Therapies Market for Neurological Disorders, till 2030
13.4.1.4. Encapsulated Cell Therapies Market for Oncological Disorders, till 2030
13.4.2. Encapsulated Cell Therapies Market: Distribution by Type of Encapsulation Material Used
13.4.2.1. Encapsulated Cell Therapies Market for Alginate-based Microcapsules, till 2030
13.4.2.2. Encapsulated Cell Therapies Market for Cellulose Hydrogels, till 2030
13.4.2.3. Encapsulated Cell Therapies Market for Medical-grade Plastics, till 2030
13.4.2.4. Encapsulated Cell Therapies Market for Red Blood Cells, till 2030
13.4.3. Encapsulated Cell Therapies Market: Distribution by Geography
13.4.3.1. Encapsulated Cell Therapies Market in North America, till 2030
13.4.3.2. Encapsulated Cell Therapies Market in Europe, till 2030
13.4.3.3. Encapsulated Cell Therapies Market in Asia-Pacific, till 2030
13.5. Encapsulated Cell Therapies for Eye Disorders: Distribution by Indication
13.5.1. Encapsulated Cell Therapies Market for Eye Disorders: Macular Telangectasia, till 2030
13.5.1.1. NT-501 (Neurotech Pharmaceuticals)
13.5.1.1.1. Target Patient Population
13.5.1.1.2. Sales Forecast
13.5.1.1.3. Geographical Distribution of Projected Opportunity
13.5.1.1.3.1. Projected Opportunity in the US
13.5.1.1.3.2. Projected Opportunity in EU5
13.5.1.1.3.3. Projected Opportunity in Rest of Europe
13.5.1.1.3.4. Projected Opportunity in Australia
13.5.2. Encapsulated Cell Therapies Market for Eye Disorders: Glaucoma, till 2030
13.5.2.1. NT-501 (Neurotech Pharmaceuticals)
13.5.2.1.1. Target Patient Population
13.5.2.1.2. Sales Forecast
13.5.2.1.3. Geographical Distribution of Projected Opportunity
13.5.2.1.3.1. Projected Opportunity in the US
13.5.2.1.3.2. Projected Opportunity in EU5
13.5.2.1.3.3. Projected Opportunity in Rest of Europe
13.5.2.1.3.4. Projected Opportunity in Australia
13.5.3. Encapsulated Cell Therapies Market for Eye Disorders: Retinitis Pigmentosa, till 2030
13.5.3.1. NT-501 (Neurotech Pharmaceuticals)
13.5.3.1.1. Target Patient Population
13.5.3.1.2. Sales Forecast
13.5.3.1.3. Geographical Distribution of Projected Opportunity
13.5.3.1.3.1. Projected Opportunity in the US
13.5.3.1.3.2. Projected Opportunity in EU5
13.5.3.1.3.3. Projected Opportunity in Rest of Europe
13.5.3.1.3.4. Projected Opportunity in Australia
13.6. Encapsulated Cell Therapies for Metabolic Disorders: Distribution by Indication
13.6.1. Encapsulated Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, till 2030
13.6.1.1. DIABECELL® (Diatranz Otsuka)
13.6.1.1.1. Target Patient Population
13.6.1.1.2. Sales Forecast
13.6.1.1.3. Geographical Distribution of Projected Opportunity
13.6.1.1.3.1. Projected Opportunity in the US
13.6.1.1.3.2. Projected Opportunity in Japan
13.6.1.1.3.3. Projected Opportunity in EU5
13.6.1.1.3.4. Projected Opportunity in Rest of Europe
13.6.1.1.3.5. Projected Opportunity in Australia
13.6.1.1.3.6. Projected Opportunity in New Zealand
13.7. Encapsulated Cell Therapies for Neurological Disorders: Distribution by Indication
13.7.1. Encapsulated Cell Therapies Market for Neurological Disorders: Ataxia Telangiectasia, till 2030
13.7.1.1. EryDex System (EryDel)
13.7.1.1.1. Target Patient Population
13.7.1.1.2. Sales Forecast
13.7.1.1.3. Geographical Distribution of Projected Opportunity
13.7.1.1.3.1. Projected Opportunity in EU5
13.7.1.1.3.2. Projected Opportunity in Rest of Europe
13.7.1.1.3.3. Projected Opportunity in the US
13.7.1.1.3.4. Projected Opportunity in Australia
13.7.1.1.3.5. Projected Opportunity in India
13.7.1.1.3.6. Projected Opportunity in Israel
13.7.1.1.3.7. Projected Opportunity in Tunisia
13.7.2. Encapsulated Cell Therapies Market for Neurological Disorders: Parkinson’s Disease, till 2030
13.7.2.1. NTCELL® (Living Cell Technologies)
13.7.2.2. Target Patient Population
13.7.2.2.1. Sales Forecast
13.7.2.2.2. Geographical Distribution of Projected Opportunity
13.7.2.2.2.1. Projected Opportunity in New Zealand
13.7.2.2.2.2. Projected Opportunity in the US
13.7.2.2.2.3. Projected Opportunity in Australia
13.7.2.2.2.4. Projected Opportunity in EU5
13.7.2.2.2.5. Projected Opportunity in Rest of Europe
13.8. Encapsulated Cell Therapies for Oncological Disorders: Distribution by Indication
13.8.1. Encapsulated Cell Therapies Market for Oncological Disorders: Pancreatic Cancer, till 2030
13.8.1.1. GRASPA® (Erytech Pharma)
13.8.1.1.1. Target Patient Population
13.8.1.1.2. Sales Forecast
13.8.1.1.3. Geographical Distribution of Projected Opportunity
13.8.1.1.3.1. Projected Opportunity in EU5
13.8.1.1.3.2. Projected Opportunity in Rest of Europe
13.8.1.1.3.3. Projected Opportunity in the US
13.8.2. Encapsulated Cell Therapies Market for Oncological Disorders: Non-Metastatic Pancreatic Cancer, till 2030
13.8.2.1. Cell-in-a-Box® (PharmaCyte Biotech)
13.8.2.1.1. Target Patient Population
13.8.2.1.2. Sales Forecast
13.8.2.1.3. Geographical Distribution of Projected Opportunity
13.8.2.1.3.1. Projected Opportunity in the US
13.8.2.1.3.2. Projected Opportunity in EU5
13.8.2.1.3.3. Projected Opportunity of Cell-in-a-Box in Rest of Europe
13.8.3. Encapsulated Cell Therapies Market for Oncological Disorders: Triple Negative Breast Cancer, till 2030
13.8.3.1. GRASPA (Erytech Pharma)
13.8.3.1.1. Target Patient Population
13.8.3.1.2. Sales Forecast
13.8.3.1.3. Geographical Distribution of Projected Opportunity
13.8.3.1.3.1. Projected Opportunity in EU5
13.8.3.1.3.2. Projected Opportunity in Rest of Europe
13.8.3.1.3.3. Projected Opportunity in the US
13.8.4. Encapsulated Cell Therapies Market for Oncological Disorders: Head and Neck Cancer, till 2030
13.8.4.1. MVX-ONCO-1 (MaxiVAX)
13.8.4.1.1. Target Patient Population
13.8.4.1.2. Sales Forecast
13.8.4.1.3. Geographical Distribution of Projected Opportunity
13.8.4.1.3.1. Projected Opportunity in EU5
13.8.4.1.3.2. Projected Opportunity in Rest of Europe
13.8.4.1.3.3. Projected Opportunity in the US
For more information, please visit https://www.rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html
14. CONCLUSION
14.1. Cell-based Pharmacological Interventions are Characterized by Diverse Challenges, Most of which can be Mitigated using Various Encapsulation Strategies
14.2. The Pipeline Features Several Mid and Late Stage Encapsulated Therapy Products, Majority of which are intended for the Treatment of Metabolic Disorders
14.3. The Fragmented Developer Landscape Includes a Mix of Small and Mid-Sized Players; at Present, North America and Europe are Major Hubs of Development Activity
14.4. The Heightened Pace of Research in this Domain is Evident from the Rise in the Number of Patents Filed / Granted and the Clinical Studies Conducted in the Recent Years
14.5. Development Efforts in this Field have Drawn Significant Capital Investments from Private and Public Investors; this is Likely to Provide the Necessary Impetus to the Market’s Future Growth
14.6. Growth in Partnership Activity Reflects the Rising Interest of Industry Stakeholders; Most Agreements are Between Technology Providers and Cell Therapy Developers
14.7. Given the Increasing Number of Licensing Deals and the Expected Approval of Multiple Mid-Late Stage Candidates, the Market is Poised to Grow at a Significant Pace in the Coming Years
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Erytech Pharma
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Alexander Scheer, Chief Scientific Officer
15.3. Defymed
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Manuel Pires, Business Developer
15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager
15.5. Aterelix
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Mick Mclean, Chief Executive Officer
15.6. Neurotech Pharmaceuticals
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Quinton Oswald, Former President and Chief Executive Officer
15.7. Seraxis
15.7.1. Company Snapshot
15.7.2. Interview Transcript: William L Rust, Founder and Chief Executive Officer
15.8. Beta-O2 Technologies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Yuval Avni, Former Chief Executive Officer
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Given the increasing number of licensing deals and the expected approval of multiple mid-late stage candidates, the encapsulated cell therapies and encapsulation technologies market is anticipated to evolve at a rapid pace over the next decade, predicts R here
News-ID: 2209735 • Views: …
More Releases from Roots Analysis
Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Prot …
According to our latest market report "Proteomics Market" by Type of Offering, Type of Instrument / Technology, Type of Reagent, Type of Proteomics Service, Application Area, End-users, Type of Operation and Geography: Industry Trends and Global Forecasts, Till 2035", the global protein expression market, valued at USD 2.7 billion in 2024, is estimated to reach USD 3.0 billion in 2025 and USD 6.3 billion by 2035, representing a CAGR of…
Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising …
09-04-2025 | Robotics & Automation
Press release from: Roots Analysis
According to Roots Analysis' latest industry report titled "Industrial Robotics Market: Industry Trends and Global Forecasts, till 2035", the global industrial robotics market is projected to grow from USD 17.64 billion in 2024 to USD 18.80 billion in 2025, reaching USD 39.03 billion by 2035 at a CAGR of 7.5% during the forecast period.
To request a quote for this report, visit:
https://www.rootsanalysis.com/industrial-robotics-market/request-quote
Market Overview
Industrial…
Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | R …
According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till…
The Conjugation and Labeling Services Market is projected to grow at a CAGR of 1 …
The complexities associated with conjugation of biomolecules and the need for click-chemistry expertise have prompted the pharmaceutical industry to rely on conjugation and labeling service providers
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market/request-quote.html
Roots Analysis is pleased to announce the publication of its recent study, titled, "Conjugation and Labeling Services Market, 2023-2035"
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.…
More Releases for Cell
Cell Isolation Cell Separation Market Size Analysis by Application, Type, and Re …
According to Market Research Intellect, the global Cell Isolation Cell Separation market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for cell isolation and separation is expanding rapidly as a result of sophisticated biotechnological…
Cell Free Protein Synthesis Market Beyond the Cell: Revolutionizing Protein Prod …
Cell-Free Protein Synthesis Market to reach over USD 457.13 Mn by the year 2031 - Exclusive Report by InsightAce Analytic
"Cell-Free Protein Synthesis Market" in terms of revenue was estimated to be worth $265.94 Mn in 2023 and is poised to reach $457.13 Mn by 2031, growing at a CAGR of 7.20% from 2024 to 2031 according to a new report by InsightAce Analytic.
Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/1445
Current…
Cell Expansion Market - Expand the Boundaries of Cell Therapy: Redefine Cell Exp …
Newark, New Castle, USA: The "Cell Expansion Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Cell Expansion Market: https://www.growthplusreports.com/report/cell-expansion-market/7939
This latest report researches the industry structure, sales, revenue,…
Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect …
Researchmoz added Most up-to-date research on "Global GMP Cell Banking Market By Type - Mammalian Cell, Microbial Cell, Insect Cell and Others" to its huge collection of research reports.
This report researches the worldwide GMP Cell Banking market size (value, capacity, production and consumption) in key regions like North America, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global GMP Cell Banking breakdown data by manufacturers, region, type…
Cell Culture Market Size, Cell Culture Market Share, Cell Culture Market Trends …
According to a new research published by Polaris Market Research the global cell culture market is anticipated to reach more than USD 49 billion by 2026. Cell culture is a rapidly emerging as an implement for analyzing and treating various disease such as Alzheimer’s and cancer.
Request for Sample of This Research Report @ https://bit.ly/2D7pZ5u
Top Key Players: -
Becton,
Dickinson and Company
Biospherix
EMD Millipore
Eppendorf AG
Merck KGaA
Sartorius AG
VWR International
Cell culture is a rapidly emerging…
Cell Banking Outsourcing Market Report 2018: Segmentation by Type of Bank (Maste …
Global Cell Banking Outsourcing market research report provides company profile for Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY…
